Oct 10, 2025 09:30AM Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

Aug 13, 2025 08:00AM Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Jul 30, 2025 09:01AM Xenetic Biosciences partner enters clinical study for lymphoma treatment

Jul 30, 2025 09:00AM Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Jul 23, 2025 08:33AM Xenetic Biosciences expands Scripps Research collaboration for DNase platform

Jul 23, 2025 08:30AM Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Jul 8, 2025 09:00AM Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Un

May 14, 2025 08:05AM Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 10, 2025 06:38AM H.C. Wainwright Reiterates Neutral Rating on Xenetic Biosciences (XBIO)

Apr 9, 2025 09:15AM Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Mar 26, 2025 09:03AM Xenetic Biosciences (XBIO) Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and E

Mar 26, 2025 09:00AM Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ew

Mar 19, 2025 08:05AM Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

Mar 13, 2025 08:30AM Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

Feb 27, 2025 09:15AM Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

Dec 17, 2024 09:15AM Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Dec 16, 2024 09:00AM Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Dec 6, 2024 06:50AM H.C. Wainwright Reiterates Neutral Rating on Xenetic Biosciences (XBIO)

Dec 5, 2024 08:47AM Xenetic Biosciences (XBIO) Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Dec 5, 2024 08:45AM Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Nov 22, 2024 09:15AM Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Nov 21, 2024 08:30AM Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Nov 13, 2024 08:30AM Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Nov 12, 2024 09:00AM Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Nov 7, 2024 09:00AM Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Oct 22, 2024 08:45AM Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Oct 21, 2024 05:08PM Xenetic Biosciences (XBIO) Files $50M Mixed Shelf

Oct 17, 2024 08:47AM Xenetic Biosciences (XBIO) Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Oct 17, 2024 08:30AM Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Sep 11, 2024 09:00AM Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 20, 2024 06:41AM H.C. Wainwright Reiterates Neutral Rating on Xenetic Biosciences (XBIO)

Aug 14, 2024 08:00AM Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update